Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) CongressBusiness Wire • 06/01/23
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023Business Wire • 05/04/23
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal HemoglobinuriaBusiness Wire • 04/25/23
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction ProgramBusiness Wire • 04/10/23
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial ResultsBusiness Wire • 03/13/23
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley BankBusiness Wire • 03/10/23
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023Business Wire • 03/07/23
Omeros Corporation Receives $200 Million Milestone Payment from Rayner SurgicalBusiness Wire • 02/06/23
Omeros: Worst Has Been Priced In, We Like Its IgAN Pipeline, Initiating With A BuySeeking Alpha • 02/04/23
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for NarsoplimabBusiness Wire • 11/08/22
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022Business Wire • 11/04/22